Osteoarthritis, Hip Clinical Trial
Official title:
Prospective Post-market Study Examining the Effectiveness of the EcoFit® Total Hip System With Implacross® E Polyethylene
Verified date | June 2021 |
Source | Implantcast North America, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to evaluate the safety and effectiveness of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery.
Status | Not yet recruiting |
Enrollment | 500 |
Est. completion date | March 30, 2027 |
Est. primary completion date | December 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: - Subject must be a candidate for a total primary hip replacement. - Subject must have degenerative joint disease, including osteoarthritis or traumatic arthritis, OR a femoral fracture which can be treated by a primary hip replacement and no other hardware - Subject has a BMI of 40.00 kg/m2 or less at the time of enrollment - Subject is likely to be available for evaluation for the duration of the study - Subject is able and willing to sign the informed consent and follow study procedures - Subject is not pregnant Exclusion Criteria: - Subject has had a prior hip replacement in the subject hip - Subject has an active cancer or is a survivor for <5 years except for squamous cell or basal cell skin cancer - Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol - Subject is currently a documented substance abuser (alcohol or other addictions) - Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic - Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity - Subject has a BMI > 40.00 kg/m2 - Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease) - Subject is a prisoner - Subject is pregnant - Subject has known materials sensitivity (to metals) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Implantcast North America, LLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery | Evaluate the overall survivorship of the devices. Observed product-related complications and revisions are recorded and documented. | 36 months | |
Secondary | Evaluate the pre to post-op change in the Harris Hip Score | The Harris Hip Score tracks pain, function/gait, performance in functional activities, and range of motion as interpreted by the surgeon. The responses determine a score which can be compared in different intervals. | Pre-op, 6 months, 12 months, 24 months, 36 months | |
Secondary | Evaluate the pre to post-op change in the WOMAC Score | The Western Ontario McMaster Arthritis Index, a questionnaire completed by the patient, tracks pain, stiffness, and difficulty with daily activities. | Pre-op, 6 months, 12 months, 24 months, 36 months | |
Secondary | Device related complications | Detect any device related complications via the adverse events reporting | Through completion of study, an average of 3.5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05773261 -
Clinical Investigation Comparing Two Different Ultra-porous Coated Surfaces of Uncemented Cups
|
N/A | |
Recruiting |
NCT05223777 -
KINCISEā¢ Surgical Automated System in Total Hip Arthroplasty (THA)
|
N/A | |
Recruiting |
NCT04731077 -
Avenir Complete Post-Market Clinical Follow-Up Study
|
N/A | |
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Completed |
NCT05070871 -
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
|
N/A | |
Not yet recruiting |
NCT06162195 -
The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement
|
N/A | |
Withdrawn |
NCT02743208 -
Evaluation of a Short Femoral Stem in Total Hip Arthroplasty
|
N/A | |
Completed |
NCT02944448 -
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
|
Phase 2 | |
Active, not recruiting |
NCT02229279 -
Evaluation of Teleconsulting on Rehabilitation After Hip and Knee Surgical Procedures
|
N/A | |
Active, not recruiting |
NCT02851992 -
A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem
|
N/A | |
Completed |
NCT01700933 -
Dose-response: Exercise Therapy on Hip Osteoarthritis
|
N/A | |
Completed |
NCT01618708 -
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
|
N/A | |
Completed |
NCT01214954 -
Early Rehabilitation After Total Hip Replacement
|
N/A | |
Active, not recruiting |
NCT00294424 -
Study on Costs and Effects of Waiting Time in Total Hip and Knee Replacements
|
N/A | |
Terminated |
NCT00588861 -
Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement
|
N/A | |
Withdrawn |
NCT05054595 -
Audio-Recorded vs. Nurse-Led Brief Mindfulness-Based Intervention
|
N/A | |
Terminated |
NCT00973141 -
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
|
Phase 2 | |
Recruiting |
NCT05014113 -
H-28 DELTA ST-C and Minima Retrospective Study.
|
||
Completed |
NCT01066936 -
Mini Stem DEXA (Dual Energy X-ray Absorptiometry)
|
||
Recruiting |
NCT06185036 -
Histological Validation of dGEMRIC Indices as a Quantitative Biomarker for Cartilage Damage in the Hip Joint
|